Author Correction: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours

A correction has been issued regarding a study published in Nature that explored the enhancement of chimeric antigen receptor natural killer (CAR-NK) cell therapy through the engineering of the OR7A10 G protein-coupled receptor (GPCR). The correction addresses an error in the visual representation of data within the article, specifically in Extended Data Figure 7k, which depicted mouse IVIS imaging results for the CAR-NK;OR7A10(STOP) group on days D21 and D27. The figures were mistakenly duplicated, leading to potential misinterpretation of the experimental outcomes. The corrected version of the article is now available in both HTML and PDF formats, ensuring accurate representation of the research findings. The study was conducted by a team of researchers affiliated with Yale University, including lead contributors Luojia Yang and Paul A. Renauer, who were jointly supervised by Lei Peng and Sidi Chen. The research spanned multiple departments and programs at Yale, including the Department of Genetics, the System Biology Institute, the Center for Cancer Systems Biology, and several interdisciplinary programs such as the Combined Program in the Biological and Biomedical Sciences and the Molecular Cell Biology, Genetics, and Development Program. Additional collaborators included researchers from the University of Chicago and Yale’s Department of Neurosurgery. The study focused on improving the efficacy of CAR-NK therapy against solid tumors by modifying the OR7A10 GPCR. This receptor, known for its role in olfactory function, was engineered to enhance the targeting capabilities of CAR-NK cells, potentially increasing their ability to recognize and destroy cancerous tissue. The research aimed to address limitations in current immunotherapies, particularly in their effectiveness against solid tumors, which often present complex microenvironments that hinder immune cell infiltration and activity. The research team comprised over two dozen scientists, many of whom hold dual appointments or affiliations across different departments at Yale. Notable contributors include Josh Saskin, Stephanie Deng, Jiayi Tu, Jing Chen, Jennifer Moliterno, Murat Gunel, and others. The collaborative nature of the project underscores the multidisciplinary approach required to advance immunotherapy strategies. The involvement of institutions such as the Yale Comprehensive Cancer Center and the Yale Stem Cell Center further highlights the integration of diverse expertise in the pursuit of innovative therapeutic solutions. While the correction pertains solely to a technical issue in the visual presentation of data, the underlying research continues to represent a significant contribution to the field of immuno-oncology. The study's focus on GPCR engineering opens new avenues for enhancing the precision and potency of CAR-based therapies. Researchers have emphasized the importance of accurate data visualization in scientific publications, as errors in graphical representations can lead to misunderstandings and affect the interpretation of experimental results. Looking ahead, the research team intends to continue exploring the implications of OR7A10 GPCR modification in CAR-NK therapy. Further studies will likely involve preclinical trials to assess the long-term safety and efficacy of the modified CAR-NK cells in treating various types of solid tumors. The ultimate goal remains to translate these findings into clinical applications that offer improved treatment options for patients with advanced or resistant cancers.